ArticleCancer gene therapy2003
Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.
Article in Cancer gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Development and Characterization of an Oncolytic Human Adenovirus-Based Vector Co-Expressing the Adenovirus Death Protein and p14 Fusion-Associated Small Transmembrane Fusogenic Protein.International journal of molecular sciences · 2024Article
- Review
- A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).Radiation oncology (London, England) · 2020Article
- Review
- The Effect of PEI-Mediated E1A on the Radiosensitivity of Hepatic Carcinoma Cells.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.Cancers · 2020Article
- Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.Frontiers in oncology · 2017Review
- The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model.Cancer gene therapy · 2013Article
- In vivo demonstration of enhanced radiotherapy using rare earth doped titania nanoparticles.Nanoscale · 2012Article
- Chapter seven--Cancer treatment with gene therapy and radiation therapy.Advances in cancer research · 2012Review
- A fully replication-competent adenovirus vector with enhanced oncolytic properties.Cancer gene therapy · 2010Article
- Increasing the efficacy of oncolytic adenovirus vectors.Viruses · 2010Article
- New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.Cancer gene therapy · 2009Article
- INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.Cancer gene therapy · 2009Article
- Armed replicating adenoviruses for cancer virotherapy.Cancer gene therapy · 2009Review
- Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development.Journal of virology · 2006Article
- Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.Cancer gene therapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We have described three potential adenovirus type 5 (Ad5)-based replication-competent cancer gene therapy vectors named KD1, KD3, and VRX-007. All three vectors overexpress an Ad5 protein named Adenovirus Death Protein (ADP, also named E3-11.6 K protein). ADP is required for efficient lysis of Ad5-infected cells and spread of virus from cell to cell, and thus its overexpression increases the oncolytic activity of the vectors. KD1 and KD3 contain mutations in the Ad5 E1A gene that knock out binding of the E1A proteins to cellular p300/CBP and pRB; these mutations allow KD1 and KD3 to grow well in cancer cells but not in normal cells. VRX-007 has wild-type E1A. Here we report that radiation increases the oncolytic activity of KD1, KD3, and VRX-007. This increased activity was observed in cultured cells, and it was not because of radiation-induced replication of the vectors. The combination of radiation plus KD3 suppressed the growth of A549 lung adenocarcinoma xenografts in nude mice more efficiently than radiation alone or KD3 alone. The combination of ADP-overexpressing vectors and radiation may have potential in treating cancer.
Indexed as
Identifiers
12637940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.